Annual Cash & Cash Equivalents
$929.03 M
+$452.02 M+94.76%
December 31, 2024
Summary
- As of February 26, 2025, RPRX annual cash & cash equivalents is $929.03 million, with the most recent change of +$452.02 million (+94.76%) on December 31, 2024.
- During the last 3 years, RPRX annual cash & cash equivalents has fallen by -$612.02 million (-39.71%).
- RPRX annual cash & cash equivalents is now -51.72% below its all-time high of $1.92 billion, reached on December 31, 2018.
Performance
RPRX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$929.03 M
-$21.03 M-2.21%
December 31, 2024
Summary
- As of February 26, 2025, RPRX quarterly cash and cash equivalents is $929.03 million, with the most recent change of -$21.03 million (-2.21%) on December 31, 2024.
- Over the past year, RPRX quarterly cash and cash equivalents has increased by +$452.02 million (+94.76%).
- RPRX quarterly cash and cash equivalents is now -61.98% below its all-time high of $2.44 billion, reached on June 30, 2020.
Performance
RPRX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
RPRX Cash And Cash Equivalents Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | +94.8% | +94.8% |
3 y3 years | -39.7% | +94.8% |
5 y5 years | +277.4% | +94.8% |
RPRX Cash And Cash Equivalents Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | -45.7% | +94.8% | -57.3% | +94.8% |
5 y | 5-year | -45.7% | +277.4% | -62.0% | +277.4% |
alltime | all time | -51.7% | +277.4% | -62.0% | +277.4% |
Royalty Pharma Cash And Cash Equivalents History
Date | Annual | Quarterly |
---|---|---|
Dec 2024 | $929.03 M(+94.8%) | $929.03 M(-2.2%) |
Sep 2024 | - | $950.05 M(-46.2%) |
Jun 2024 | - | $1.76 B(+109.3%) |
Mar 2024 | - | $843.00 M(+76.7%) |
Dec 2023 | $477.01 M(-72.1%) | $477.01 M(-49.1%) |
Sep 2023 | - | $936.45 M(-56.9%) |
Jun 2023 | - | $2.17 B(+10.0%) |
Mar 2023 | - | $1.98 B(+15.5%) |
Dec 2022 | $1.71 B | $1.71 B(+72.5%) |
Sep 2022 | - | $991.63 M(-53.0%) |
Jun 2022 | - | $2.11 B(+17.7%) |
Date | Annual | Quarterly |
---|---|---|
Mar 2022 | - | $1.79 B(+16.3%) |
Dec 2021 | $1.54 B(+52.8%) | $1.54 B(-14.4%) |
Sep 2021 | - | $1.80 B(+57.7%) |
Jun 2021 | - | $1.14 B(+61.2%) |
Mar 2021 | - | $708.81 M(-29.7%) |
Dec 2020 | $1.01 B(+309.7%) | $1.01 B(-35.0%) |
Sep 2020 | - | $1.55 B(-36.4%) |
Jun 2020 | - | $2.44 B(+291.3%) |
Mar 2020 | - | $624.37 M(+153.6%) |
Dec 2019 | $246.20 M(-87.2%) | $246.20 M |
Dec 2018 | $1.92 B | - |
FAQ
- What is Royalty Pharma annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Royalty Pharma?
- What is Royalty Pharma annual cash & cash equivalents year-on-year change?
- What is Royalty Pharma quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Royalty Pharma?
- What is Royalty Pharma quarterly cash and cash equivalents year-on-year change?
What is Royalty Pharma annual cash & cash equivalents?
The current annual cash & cash equivalents of RPRX is $929.03 M
What is the all time high annual cash & cash equivalents for Royalty Pharma?
Royalty Pharma all-time high annual cash & cash equivalents is $1.92 B
What is Royalty Pharma annual cash & cash equivalents year-on-year change?
Over the past year, RPRX annual cash & cash equivalents has changed by +$452.02 M (+94.76%)
What is Royalty Pharma quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of RPRX is $929.03 M
What is the all time high quarterly cash and cash equivalents for Royalty Pharma?
Royalty Pharma all-time high quarterly cash and cash equivalents is $2.44 B
What is Royalty Pharma quarterly cash and cash equivalents year-on-year change?
Over the past year, RPRX quarterly cash and cash equivalents has changed by +$452.02 M (+94.76%)